Correction to: Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients.
作者信息
Pri-Paz Basson Yael, Tayer-Shifman Oshrat E, Naser Rawand, Tartakover Matalon Shelly, Kimhi Oded, Gepstein Raz, Halperin Tamar, Ziv-Baran Tomer, Ziv Amit, Parikh Roma, Kivity Shaye, Levy Yair
机构信息
Rheumatology Unit, Meir Medical Center, Kfar Saba, Israel.
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
出版信息
Clin Rheumatol. 2022 Dec;41(12):3925. doi: 10.1007/s10067-022-06412-8.
Abstract
摘要
相似文献
1
Correction to: Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients.
Clin Rheumatol. 2022 Dec;41(12):3925. doi: 10.1007/s10067-022-06412-8.
2
Correction: .
Ann Rheum Dis. 2022 Jul;81(7):e133. doi: 10.1136/annrheumdis-2021-220647corr1.
3
Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases.
Rheumatology (Oxford). 2022 Nov 2;61(11):4482-4490. doi: 10.1093/rheumatology/keac140.
4
Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series.
Rheumatology (Oxford). 2021 Oct 9;60(SI):SI90-SI95. doi: 10.1093/rheumatology/keab345.
5
Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy.
Intern Med. 2022 Jul 1;61(13):1953-1958. doi: 10.2169/internalmedicine.9223-21. Epub 2022 Apr 23.
6
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases.
Front Immunol. 2022 Oct 13;13:1016927. doi: 10.3389/fimmu.2022.1016927. eCollection 2022.
7
Immunogenicity and safety of the CoronaVac and BNT162b2 Covid-19 vaccine in patients with inflammatory rheumatic diseases and healthy adults: comparison of different vaccines.
Inflammopharmacology. 2022 Dec;30(6):2089-2096. doi: 10.1007/s10787-022-01089-6. Epub 2022 Oct 25.
8
Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications.
Rheumatology (Oxford). 2022 Nov 2;61(11):4263-4272. doi: 10.1093/rheumatology/keac103.
9
Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab.
Vaccines (Basel). 2022 Jun 6;10(6):901. doi: 10.3390/vaccines10060901.
10
Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study.
Ann Rheum Dis. 2022 Nov;81(11):1594-1602. doi: 10.1136/ard-2022-222550. Epub 2022 Jul 22.
引用本文的文献
1
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase.
J Transl Autoimmun. 2023 Oct 9;7:100212. doi: 10.1016/j.jtauto.2023.100212. eCollection 2023 Dec.
2
Steroid treatment suppresses the CD4 T-cell response to the third dose of mRNA COVID-19 vaccine in systemic autoimmune rheumatic disease patients.
Sci Rep. 2022 Dec 6;12(1):21056. doi: 10.1038/s41598-022-25642-z.
Zotero 插件